Recce Pharmaceuticals Ltd News

Recce Pharmaceuticals Ltd: Regulatory Approval for Registrational Phase 3 R327G Trial

Dec 8, 2024 17:05 ET

Recce Pharmaceuticals Ltd: Trading Halt

Dec 4, 2024 17:21 ET

Recce Pharmaceuticals Ltd: Australia Patent Granted for RECCE Anti-Infectives

Nov 25, 2024 16:37 ET

Recce Pharmaceuticals Ltd: Ethics Approval for Registrational Ph3 R327G Clinical Trial

Nov 10, 2024 17:16 ET

Recce Pharmaceuticals Ltd: Phase II ABSSSI Clinical Trial Advances to Final Stages

Nov 4, 2024 18:12 ET

Recce Pharmaceuticals Ltd: Efficacy Data & Approval to Continue Ph II ABSSSI Trial

Oct 27, 2024 18:44 ET

Recce Pharmaceuticals Ltd: Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway

Oct 8, 2024 18:07 ET

Recce Pharmaceuticals Ltd: 2024 Annual General Meeting

Sep 16, 2024 02:47 ET

Recce Pharmaceuticals Ltd: Appendix 4G

Aug 30, 2024 03:19 ET

Recce Pharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jul 25, 2024 20:44 ET

Recce Pharmaceuticals Ltd: US Department of Defense Grants US $2m for R327G

Jul 14, 2024 19:50 ET

Recce Pharmaceuticals Ltd: Change of Auditor

Jul 11, 2024 01:25 ET

Recce Pharmaceuticals Ltd: R327 Efficacy against WHO Priority Pathogen Acinetobacter B

Jul 7, 2024 19:53 ET

Recce Pharmaceuticals Ltd: Trading Halt

Jun 30, 2024 19:33 ET

Recce Pharmaceuticals Ltd: Clarification - Phase I/II UTI/Urosepsis Fast Infusion Trial

Jun 30, 2024 19:07 ET

Recce Pharmaceuticals Ltd: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete

Jun 27, 2024 19:21 ET

Recce Pharmaceuticals Ltd: Ethics Approval Broadens to All Topical Infections

Jun 23, 2024 19:55 ET

Recce Pharmaceuticals Ltd: Further R&D Rebate Approved

Jun 18, 2024 00:40 ET

Recce Pharmaceuticals Ltd: R327 added to WHO List of Antibacterial Products

Jun 17, 2024 20:04 ET

Recce Pharmaceuticals Ltd: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial

Jun 10, 2024 18:39 ET